Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This NIS is a multi-centre, observational, descriptive, cross-sectional study including all consecutive patients with Acute Coronary Syndrome (ACS) and a single-arm, prospective, longitudinal cohort study which will include patients hospitalized for ACS and who are with ticagrelor on discharge from hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A | PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST | ||
| Part B | Patients on ticagrelor at the time of discharge from hospital |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients receiving different types of short-term antithrombotic treatment according to different type of acute coronary syndrome (STEMI - ST-elevation myocardial infarction, NSTE(Non-ST-elevation)-ACS and Unstable Angina). (Part A) | Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 | 1st Jan of 2012-1st March of 2015 |
| Proportion of patients taking ticagrelor with cardiovascular (CV) events after discharge from hospital depending on DAT (Dual Antiplatelet Therapy) duration. (Part B) | During follow up | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients who undergo invasive or non-invasive short-term clinical management according to different type of acute coronary syndrome (STEMI, NSTE-ACS and Unstable Angina). (Part A) | Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 | 1st Jan of 2012-1st March of 2015 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Study includes patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and who have a final diagnosis of Unstable Angina (UA), Myocardial Infarction (MI) and were discharged. Including transferred to another medical institution after 24 hours from the moment of hospitalization; transferred from other medical institutions within 24 hours from the moment of initial hospitalization to hospital.
Principal of choice in the Single-cohort study: only patients with ticagrelor at discharged.
Patients received the standard medical care as determined by the treating cardiologist.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vladimir Bulatov, MCMD | AstraZeneca | Study Director |
| Eleva Oschepkova, MD, PROFESSOR OF CARDIOLOGY | Russian Cardiology Research and Production Complex | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Arkhangelsk | Russia | ||||
| Research Site |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Time from first symptoms onset to the time of hospitalization (Part A) |
Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 |
| 1st Jan of 2012-1st March of 2015 |
| Proportion of patients receiving different types of ACS treatment depending on ACS symptoms duration prior hospitalization. (Part A) | Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 | 1st Jan of 2012-1st March of 2015 |
| Patients demographic and baseline characteristics (age, gender, weight, height). (Part A) | Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 | 1st Jan of 2012-1st March of 2015 |
| Proportion of patients with different type of coronary intervention strategies. (Part A) | Patients included in Federal ACS Registry from 1st Jan of 2012 till 1st March of 2015 | 1st Jan of 2012-1st March of 2015 |
| Proportion of patients who is on ticagrelor treatment during 0-3 months, >3-6 months, >6-9 months, >9-12 months. (Part B) | During follow up | Up to 2 years |
| Proportion of patients with ticagrelor treatment interruptions according to different clinical and non-clinical events (bleeds, planned and non-planned medical interventions, etc.) during follow-up. (Part B) | During follow-up period | Up to 2 years |
| Proportion of patients with thrombo-embolic events during follow-up depending on DAT therapy duration. (Part B) | During follow-up period | Up to 2 years |
| Proportion of patients who discontinued ticagrelor and reason to discontinue ticagrelor treatment. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients with significant violations of treatment regimen with ticagrelor. (Part B) | during follow-up period | Up to 2 years |
| Start and stop dates of dual antipatelet therapy and ticagrelor (as part of DAT) and duration of exposure to DAT and ticagrelor in real-life setting. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients who discontinued DAT and the reason of discontinuation of DAT in real-life setting. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients who change DAT components and reason to change of DAT. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients with CV-events (recurrent Myocardial Infarction-MI, stroke, ischemia-driven revascularization, death, etc.) in long-term perspective (second year) after index event in real-life setting. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients using different type of antithrombotic therapy in long-term perspective (second year) after index event. (Part B) | during follow-up period | Up to 2 years |
| Proportion of patients who managed by cardiologist, therapist and other physician after discharge from the hospital. (Part B) | during follow-up period | Up to 2 years |
| Cheboksary |
| Russia |
| Research Site | Irkutsk | Russia |
| Research Site | Kazan' | Russia |
| Research Site | Kemerovo | Russia |
| Research Site | Moscow | Russia |
| Research Site | Novosibirsk | Russia |
| Research Site | Petrozavodsk | Russia |
| Research Site | Ryazan | Russia |
| Research Site | Saint Petersburg | Russia |
| Research Site | Stavropol | Russia |
| Research Site | Tomsk | Russia |
| Research Site | Tyumen | Russia |
| Research Site | Ufa | Russia |
| Research Site | Vladivostok | Russia |